Tenofovir and Kidney Health: A Study from India
Author Information
Author(s): Ketan K. Patel, Atul K. Patel, Rajiv R. Ranjan, Apurva R. Patel, Jagdish K. Patel
Primary Institution: Vedanta Institute of Medical Sciences, Ahmedabad, India
Hypothesis
Is tenofovir (TDF) associated with renal dysfunction in patients receiving antiretroviral therapy?
Conclusion
TDF-based treatment is associated with mild but reversible renal dysfunction, particularly in patients receiving boosted protease inhibitors.
Supporting Evidence
- 83 out of 1,271 patients developed renal dysfunction while on TDF.
- Renal dysfunction was more common in patients receiving boosted protease inhibitors compared to those on NNRTI.
- All patients with impaired serum creatinine recovered after stopping TDF.
Takeaway
This study found that some people taking a medicine called tenofovir for HIV can have kidney problems, but these problems usually go away if they stop taking the medicine.
Methodology
This was an observational longitudinal cohort study evaluating patients on a TDF-based regimen for renal function over time.
Potential Biases
There may be bias in patient selection and reporting of renal dysfunction.
Limitations
The study is limited by its observational design and the potential for unmeasured confounding factors.
Participant Demographics
{"age":{"median":44,"range":"30-72"},"sex":{"male":63,"female":15},"weight":{"median":60,"range":"40-112"}}
Statistical Information
P-Value
0.003
Confidence Interval
15-935 days
Statistical Significance
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website